Previous Close | 3.1300 |
Open | 3.3200 |
Bid | 2.6400 x 2900 |
Ask | 3.0800 x 800 |
Day's Range | 2.9500 - 3.3300 |
52 Week Range | 2.8500 - 33.3700 |
Volume | |
Avg. Volume | 563,552 |
Market Cap | 222.661M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.7500 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.50 |
Biotech companies spend a lot of money. They spend it on research and development, clinical trials, and (if they are lucky) marketing and a salesforce. Bringing a new pharmaceutical or medical device to market is an expensive proposition.
LA JOLLA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the quarter ended March 31, 2022. “We are on track to begin shipping G4 instruments to our customers in the second quarter. We are encouraged by the robust external validation through our Bet
Singular’s G4 Sequencing Platform with NVIDIA Clara Parabricks secondary analysis tools delivers accelerated results for prominent applications including whole genome sequencingLA JOLLA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the company is collaborating with NVIDIA to validate and optimize the performance